<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List
href="Pediatric_Oncology_Treatment_Protocols_Updated_NCCN.fld/filelist.xml">
<link rel=Edit-Time-Data
href="Pediatric_Oncology_Treatment_Protocols_Updated_NCCN.fld/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Resnick, Adam C</o:Author>
  <o:LastAuthor>Resnick, Adam C</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>2</o:TotalTime>
  <o:Created>2025-11-09T16:44:00Z</o:Created>
  <o:LastSaved>2025-11-09T16:44:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>7752</o:Words>
  <o:Characters>44192</o:Characters>
  <o:Paragraphs>en</o:Paragraphs>
  <o:Lines>368</o:Lines>
  <o:Paragraphs>103</o:Paragraphs>
  <o:CharactersWithSpaces>51841</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:CustomDocumentProperties>
  <o:generator dt:dt="string">ChatGPT Deep Research</o:generator>
 </o:CustomDocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData
href="Pediatric_Oncology_Treatment_Protocols_Updated_NCCN.fld/themedata.thmx">
<link rel=colorSchemeMapping
href="Pediatric_Oncology_Treatment_Protocols_Updated_NCCN.fld/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>18 pt</w:DrawingGridHorizontalSpacing>
  <w:DrawingGridVerticalSpacing>18 pt</w:DrawingGridVerticalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <w:DoNotOptimizeForBrowser/>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" Priority="99" Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Mention"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Hashtag"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Unresolved Mention"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:77;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 -2147483647 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
	{font-family:Aptos;
	panose-1:2 11 0 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 3 0 0 415 0;}
@font-face
	{font-family:"Aptos Display";
	panose-1:2 11 0 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 3 0 0 415 0;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-520092929 1073806591 9 0 415 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:"Body Text";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:0pt;
	mso-ansi-language:EN;
	font-weight:normal;}
h2
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:"Body Text";
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h3
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-style-next:"Body Text";
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h4
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-style-next:"Body Text";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 5 Char";
	mso-style-next:"Body Text";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h6
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 6 Char";
	mso-style-next:"Body Text";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-ansi-language:EN;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 7 Char";
	mso-style-next:"Body Text";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-ansi-language:EN;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 8 Char";
	mso-style-next:"Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-ansi-language:EN;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 9 Char";
	mso-style-next:"Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-ansi-language:EN;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-priority:9;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-unhide:no;
	mso-style-link:"Caption Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.MsoFootnoteReference
	{mso-style-unhide:no;
	mso-style-parent:"Caption Char";
	vertical-align:super;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpFirst, li.MsoSubtitleCxSpFirst, div.MsoSubtitleCxSpFirst
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpMiddle, li.MsoSubtitleCxSpMiddle, div.MsoSubtitleCxSpMiddle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpLast, li.MsoSubtitleCxSpLast, div.MsoSubtitleCxSpLast
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	mso-style-next:"Body Text";
	margin-top:5.0pt;
	margin-right:24.0pt;
	margin-bottom:5.0pt;
	margin-left:24.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
a:link, span.MsoHyperlink
	{mso-style-unhide:no;
	mso-style-parent:"Caption Char";
	color:#156082;
	mso-themecolor:accent1;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-unhide:no;
	color:#96607D;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{mso-style-priority:39;
	mso-style-qformat:yes;
	mso-style-parent:"Heading 1";
	mso-style-next:"Body Text";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;}
p.FirstParagraph, li.FirstParagraph, div.FirstParagraph
	{mso-style-name:"First Paragraph";
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	mso-style-next:"Body Text";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.Compact, li.Compact, div.Compact
	{mso-style-name:Compact;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	margin-top:1.8pt;
	margin-right:0in;
	margin-bottom:1.8pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Title;
	mso-ansi-font-size:28.0pt;
	mso-bidi-font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Subtitle;
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;}
p.Author, li.Author, div.Author
	{mso-style-name:Author;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.AbstractTitle, li.AbstractTitle, div.AbstractTitle
	{mso-style-name:"Abstract Title";
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Abstract;
	margin-top:15.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.Abstract, li.Abstract, div.Abstract
	{mso-style-name:Abstract;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:"Body Text";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	mso-ansi-font-size:20.0pt;
	mso-bidi-font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	mso-ansi-font-size:16.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 9";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;}
p.FootnoteBlockText, li.FootnoteBlockText, div.FootnoteBlockText
	{mso-style-name:"Footnote Block Text";
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"Footnote Text";
	mso-style-next:"Footnote Text";
	margin-top:5.0pt;
	margin-right:24.0pt;
	margin-bottom:5.0pt;
	margin-left:24.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.DefinitionTerm, li.DefinitionTerm, div.DefinitionTerm
	{mso-style-name:"Definition Term";
	mso-style-unhide:no;
	mso-style-next:Definition;
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.Definition, li.Definition, div.Definition
	{mso-style-name:Definition;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.TableCaption, li.TableCaption, div.TableCaption
	{mso-style-name:"Table Caption";
	mso-style-unhide:no;
	mso-style-parent:Caption;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.ImageCaption, li.ImageCaption, div.ImageCaption
	{mso-style-name:"Image Caption";
	mso-style-unhide:no;
	mso-style-parent:Caption;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.Figure, li.Figure, div.Figure
	{mso-style-name:Figure;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.CaptionedFigure, li.CaptionedFigure, div.CaptionedFigure
	{mso-style-name:"Captioned Figure";
	mso-style-unhide:no;
	mso-style-parent:Figure;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.CaptionChar
	{mso-style-name:"Caption Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Caption;}
span.VerbatimChar
	{mso-style-name:"Verbatim Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Caption Char";
	mso-style-link:"Source Code";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.SectionNumber
	{mso-style-name:"Section Number";
	mso-style-unhide:no;
	mso-style-parent:"Caption Char";}
p.SourceCode, li.SourceCode, div.SourceCode
	{mso-style-name:"Source Code";
	mso-style-unhide:no;
	mso-style-link:"Verbatim Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	word-break:break-all;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.KeywordTok
	{mso-style-name:KeywordTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.DataTypeTok
	{mso-style-name:DataTypeTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#902000;}
span.DecValTok
	{mso-style-name:DecValTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.BaseNTok
	{mso-style-name:BaseNTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.FloatTok
	{mso-style-name:FloatTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.ConstantTok
	{mso-style-name:ConstantTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#880000;}
span.CharTok
	{mso-style-name:CharTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.SpecialCharTok
	{mso-style-name:SpecialCharTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.StringTok
	{mso-style-name:StringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.VerbatimStringTok
	{mso-style-name:VerbatimStringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.SpecialStringTok
	{mso-style-name:SpecialStringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BB6688;}
span.ImportTok
	{mso-style-name:ImportTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:green;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.CommentTok
	{mso-style-name:CommentTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.DocumentationTok
	{mso-style-name:DocumentationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BA2121;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.AnnotationTok
	{mso-style-name:AnnotationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.CommentVarTok
	{mso-style-name:CommentVarTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.OtherTok
	{mso-style-name:OtherTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;}
span.FunctionTok
	{mso-style-name:FunctionTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#06287E;}
span.VariableTok
	{mso-style-name:VariableTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#19177C;}
span.ControlFlowTok
	{mso-style-name:ControlFlowTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.OperatorTok
	{mso-style-name:OperatorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#666666;}
span.BuiltInTok
	{mso-style-name:BuiltInTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:green;}
span.ExtensionTok
	{mso-style-name:ExtensionTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.PreprocessorTok
	{mso-style-name:PreprocessorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BC7A00;}
span.AttributeTok
	{mso-style-name:AttributeTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#7D9029;}
span.RegionMarkerTok
	{mso-style-name:RegionMarkerTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.InformationTok
	{mso-style-name:InformationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.WarningTok
	{mso-style-name:WarningTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.AlertTok
	{mso-style-name:AlertTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:red;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.ErrorTok
	{mso-style-name:ErrorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:red;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.NormalTok
	{mso-style-name:NormalTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:Consolas;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:0pt;
	mso-ligatures:none;
	mso-ansi-language:EN;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:10.0pt;}
 /* Page Definitions */
 @page
	{mso-footnote-numbering-restart:each-section;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;
	mso-footnote-numbering-restart:each-section;}
 /* List Definitions */
 @list l0
	{mso-list-id:43408;
	mso-list-template-ids:-94371288;}
@list l0:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level3
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level4
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level5
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level6
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level7
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level8
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level9
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l1
	{mso-list-id:43409;
	mso-list-template-ids:-1987154806;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
@list l1:level4
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level5
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
@list l1:level7
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level8
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
@list l2
	{mso-list-id:11112961;
	mso-list-template-ids:1848827062;}
@list l2:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:10.0pt;
	mso-para-margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-ansi-language:EN;}
table.Table
	{mso-style-name:Table;
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:10.0pt;
	mso-para-margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-ansi-language:EN;}
table.TableFirstRow
	{mso-style-name:Table;
	mso-table-condition:first-row;
	mso-style-noshow:yes;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-tstyle-vert-align:bottom;
	mso-tstyle-border-bottom:.25pt solid windowtext;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link="#156082" vlink="#96607D" style='tab-interval:.5in;
word-wrap:break-word'>

<div class=WordSection1>

<h1><a name=Xf38c977c61f036247de3444d788f9a19e1e08b1></a><a name=content></a><a
name=header></a><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span lang=EN>Pediatric Oncology Treatment
Protocols Reference</span></span></span></h1>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span lang=EN>Below is a reference guide to be
used in conjunction with <span style='mso-spacerun:yes'></span>table CBTN_REDCAP_Protocols.csv
(CSV format) detailing each protocol (from the provided REDCap list) with
structured information. The table includes the protocol ID, specific arm (if
applicable), key treatment components (chemotherapy agents, radiation modality,
targeted/immunotherapy), the treatment sequence/phases, dosing or radiation
specifics when available, and notes (including patient eligibility or context).
Citations to authoritative sources are provided for verification.</span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><b><span lang=EN>Note:</span></b><span lang=EN>
Some entries in the REDCap list correspond to biology or pilot studies (e.g.,
ANBL00B1 is a biology study, ANBL00P1 a pilot study) rather than specific
treatment regimens; those are included with minimal description. For brevity,
similar protocols or arms are grouped, and dosing is summarized. Full protocol
details can be found in referenced clinical trial documents or publications.</span></span></span></p>

<h2><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><a name=reference-guide-and-inference-guidelines><span
lang=EN>Reference Guide and Inference Guidelines</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
lang=EN>This section provides a narrative overview of these pediatric oncology
protocols and guidance for inferring protocol enrollment from treatment
details, even if not explicitly stated in a clinical note. The protocols are
organized by disease category, and key identifying features of their regimens
are highlighted. By recognizing drug combinations, dosing schedules, and
sequence of therapy, one can often deduce if a patient was treated per a
specific protocol.</span></span></span></span></p>

<h3><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><a
name=X2a83c179a0864b78f68df3012102e0a5b4b2856><span lang=EN>Leukemia/Lymphoma
Protocols (COG AALL, ANHL, etc.)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><b><span lang=EN>Acute
Lymphoblastic Leukemia (ALL)</span></b><span lang=EN>  e.g., <i>COG AALL0434</i>
for T-cell ALL: - <b>Hallmark regimen</b>: Multi-phase chemotherapy (Induction,
Consolidation, Intensification, Maintenance) using vincristine, anthracyclines,
corticosteroids, cytarabine, cyclophosphamide, methotrexate, 6-mercaptopurine,
and asparaginase. T-ALL protocols often include early cranial radiation for
CNS-positive disease and nelarabine for T-cell ALL</span></span></span></span></span><a
href="https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric#:~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[3]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><a
href="https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/#:~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[4]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>. -
<b>Inference clues</b>: Presence of nelarabine in a pediatric ALL regimen
strongly suggests AALL0434 or successor T-ALL trials</span></span></span></span></span><a
href="https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric#:~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[3]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>.
Cranial irradiation (1218 Gy) during consolidation for CNS3 patients also
aligns with AALL0434</span></span></span></span></span><a
href="https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/#:~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[4]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>.
If a patients chemo orders follow an ABFM backbone (Adriamycin, high-dose
MTX or Capizzi MTX, etc.) with or without nelarabine, it likely maps to this
trial.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><b><span lang=EN>Non-Hodgkin
Lymphoma (NHL)</span></b><span lang=EN>  e.g., <i>CCG-A5971 (lymphoblastic
lymphoma)</i> and <i>ANHL0131 (B-cell NHL)</i>: - <b>Hallmark regimen</b>:
BFM-based intensive chemotherapy for lymphoblastic lymphoma (similar to ALL
therapy)</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[79]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>,
or short intense courses (COPADM, CYM) for B-cell NHL (French LMB protocol). - <b>Inference
clues</b>: For lymphoblastic lymphoma, ALL-like treatment (vincristine,
prednisone, doxorubicin, PEG-asparaginase, cyclophosphamide) suggests CCG-A5971
or similar. Presence of high-dose methotrexate and CNS prophylaxis without
overt leukemia diagnosis indicates lymphoma protocol. If a note mentions BFM
regimen B or intrathecal therapy with no leukemia, likely a lymphoma trial</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[79]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>.
For B-NHL (e.g. Burkitt), regimens named FAB/LMB or drugs like high-dose
cyclophosphamide, methotrexate (38 g/m), and cytarabine in short cycles
indicate an LMB-based trial (such as ANHL1131 or predecessor ANHL0131,
especially if rituximab was added in later trials).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><b><span lang=EN>Hodgkin
Lymphoma</span></b><span lang=EN>  e.g., <i>COG AAHodgkin trials</i>: - <b>Hallmark
regimen</b>: ABVD or OEPA-COPDac chemotherapy and involved-field radiation for
advanced disease; abbreviated chemo (e.g., vincristine + vinblastine +
prednisone + doxorubicin) for low risk. - <b>Inference clues</b>: Mention of
ABVD agents in a pediatric context (dosed over multiple cycles) and low-dose
IF-RT (~1525 Gy) suggests a COG Hodgkin protocol such as AAHOD0031 or
predecessor. Additional vinblastine in consolidation (as in ANHL0131</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=164%20,ANHL0131%3A%20Experimental%3A%20Consolidation%20with%20Vinblastine"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>[67]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'><span lang=EN>)
would specifically point to that experimental arm.</span></span></span></span></span></p>

<span style='mso-bookmark:X2a83c179a0864b78f68df3012102e0a5b4b2856'></span>

<h3><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><a
name=Xc9a637d338794c1a78ab22ec21473a54196862e><span lang=EN>CNS Tumor Protocols
(Medulloblastoma/PNET, Ependymoma, High-Grade Glioma, DIPG)</span></a></span></span></span></h3>

<p class=MsoNormal><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>**2024
NCCN Update:** Only WNT-subtype medulloblastoma protocols (e.g., SJMB12, PNET5)
support reduced-dose CSI (18 Gy). Include molecular risk stratification (WNT,
SHH, G3, G4) as a key inference element.</span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><b><span lang=EN>Standard-Risk
Medulloblastoma</span></b><span lang=EN> (age 3, M0): Protocols like <i>COG
ACNS0331</i> and earlier CCG/POG trials: - <b>Hallmark regimen</b>: Surgery 
CSI ~23.4 Gy with weekly vincristine  posterior fossa or tumor-bed boost
(~5455.8 Gy)</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[6]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN> 
69 cycles of platinum-based adjuvant chemotherapy (e.g., cisplatin, CCNU,
vincristine)</span></span></span></span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
<b>Inference clues</b>: A child age 38 receiving exactly 23.4 Gy CSI (lower
than older standard 36 Gy) followed by monthly cycles of cisplatin, lomustine,
and vincristine indicates an average-risk medulloblastoma protocol</span></span></span></span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.
If the note mentions <i>reduced-dose craniospinal irradiation</i> and
maintenance chemo, it likely aligns with ACNS0331 or CCG-9961. Involvement of
an IFRT vs PFRT comparison or cognitive evaluations suggests ACNS0331</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[6]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><b><span lang=EN>High-Risk
Medulloblastoma</span></b><span lang=EN> (metastatic or subtotal resection):
Protocols like <i>COG ACNS0332</i>: - <b>Hallmark regimen</b>: Surgery  CSI 36
Gy (full dose) + concurrent <b>carboplatin</b> (radiosensitizer in experimental
arm)</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[11]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN> 
intensive adjuvant chemo (often alternating cycles of
cisplatin/vincristine/cyclophosphamide and high-dose methotrexate or
cyclophosphamide/etoposide)   biologic agent (isotretinoin was tested)</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[15]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
<b>Inference clues</b>: Documentation of carboplatin given <b>during radiation</b>
is a strong pointer to ACNS0332</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[11]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>
(or St. Jude trial SJMB03 if done off-study, but COG is more likely).
Additionally, maintenance <b>isotretinoin (13-cis-retinoic acid)</b> for ~612
months in a medulloblastoma patient is a distinctive feature of ACNS0332 arms
C/D</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[15]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.
If a patients regimen includes 6 cycles of cisplatin, cyclophosphamide,
vincristine, followed by isotretinoin, that essentially confirms ACNS0332
participation</span></span></span></span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><b><span lang=EN>Infant
Brain Tumors (Medulloblastoma/PNET &lt;3 years)</span></b><span lang=EN>:
Trials like <i>COG ACNS0334</i>, <i>Head Start II/III</i>, <i>SJYC07</i>: - <b>Hallmark
regimen</b>: Omit upfront radiation; use intensive chemo to delay/avoid RT.
Often <b>induction chemotherapy</b> (multiple cycles including high-dose
methotrexate in some protocols) followed by <b>myeloablative chemotherapy with
stem cell transplant</b>. - <b>Inference clues</b>: Infants treated with <b>high-dose
methotrexate</b> as part of initial therapy (with leucovorin rescue) followed
by stem cell transplant likely were on ACNS0334 (if on a COG trial)</span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=ARM%20II%3A%20Patients%20receive%20vincristine,for%203%20courses%20in%20the"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[31]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN> or
SJYC07. If no methotrexate but multiple induction cycles and then a single or
tandem transplant, it suggests Head Start protocol. For example, <b>Head Start</b>
is indicated by 5 drug induction (vincristine, cisplatin, etoposide,
cyclophosphamide,  methotrexate) and <b>3 sequential transplants</b> (Head
Start II) or a single transplant (Head Start III). A note of
thiotepa/carboplatin transplant in a toddler without radiation implies Head
Start or ACNS0334 consolidation</span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[74]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.
Also, mention of an <b>autologous transplant in a patient under 3 with a brain
tumor</b> strongly signals an infant brain tumor trial (since standard
medulloblastoma therapy does not use transplant except in trials).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><b><span lang=EN>Ependymoma</span></b><span
lang=EN>: Trials like <i>COG ACNS0831</i>: - <b>Hallmark regimen</b>: Maximal
surgical resection  <b>Conformal radiation (usually 5459.4 Gy)</b>. The role
of chemo is controversial; ACNS0831 tested <b>post-RT maintenance chemo (VCEC:
vincristine, cisplatin, etoposide, cyclophosphamide)</b></span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=I,VCEC"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN> vs
observation. - <b>Inference clues</b>: If a note indicates a child with
ependymoma received radiation followed by <b>four cycles of vincristine,
cisplatin, cyclophosphamide, etoposide</b>, it suggests they were on ACNS0831
and randomized to chemotherapy</span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=I,VCEC"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.
Conversely, radiation with no chemo (beyond possible induction attempts)
suggests either ACNS0831 observation arm or treatment off-trial (since previous
standards didnt use adjuvant chemo after radiation). The timing of radiation
is also telling: ACNS0831 mandated starting RT within 38 weeks of surgery</span></span></span></span></span><a
href="https://www.sciencedirect.com/science/article/pii/S245210942100049X#:~:text=Effect%20of%20Postoperative%20Radiation%20Therapy,The%20purpose%20of%20this"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[56]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN> 
a prompt radiation start in an infant (12 months old) means they likely
entered this trial rather than delaying RT.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><b><span lang=EN>High-Grade
Glioma (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG)</span></b><span
lang=EN>: - For <b>supratentorial HGG (glioblastoma/anaplastic astrocytoma)</b>,
the standard of care adopted from adults is concurrent radiotherapy with daily
temozolomide followed by adjuvant temozolomide (the Stupp regimen). Trials
have attempted to improve this: - <i>ACNS0423</i> added <b>lomustine</b> to
adjuvant TMZ</span></span></span></span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[36]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=resection%20extent,Four%20weeks%20after"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[35]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
<i>ACNS0822</i> randomized patients to add <b>vorinostat</b> or <b>bevacizumab</b>
versus continue with TMZ alone during RT</span></span></span></span></span><a
href="https://ncicirb.org/node/2696#:~:text=A%20Randomized%20Phase%20II%2FIII%20Study,7921%29%20and%20Local"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[49]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><a
href="https://www.qarc.org/COG/HighGradeGliomas_.pdf#:~:text=,%E2%80%93"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[53]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
<b>Inference clues (HGG)</b>: Any mention of <b>temozolomide given during
radiation and for 6 cycles after</b> in a childs glioma treatment indicates a
Stupp-based protocol. If additionally <b>lomustine</b> is given (e.g., CCNU
every 6 weeks noted), that identifies ACNS0423</span></span></span></span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[36]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>.
If an antibody like <b>bevacizumab</b> or HDAC inhibitor <b>vorinostat</b> is
used upfront with RT, the child likely participated in ACNS0822 (bevacizumab
use concurrently with radiation in newly diagnosed glioma is not standard
outside of trials)</span></span></span></span></span><a
href="https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264#:~:text=TEMOZOLOMIDE%20,GROUP%20STUDY%20ACNS0822"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[80]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
For <b>DIPG/DMG (brainstem gliomas)</b>, standard therapy is radiation alone.
Many trials layered experimental therapies: - <i>ACNS0621</i> and PBTC-030:
added <b>vorinostat</b> (HDAC inhibitor) to radiation</span></span></span></span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/#:~:text=ACNS0822%20was%20a%20feasibility%20and,received%20vorinostat%20230%20mg%2Fm2%2Fdose"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[40]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>. -
<i>PNOC</i> and PBTC trials: tested various targeted agents (e.g.,
panobinostat, EGFR or PDGF inhibitors, ONC201, etc.) with radiation. - <i>SJ-DIPG-BATS</i>:
tested <b>bevacizumab, erlotinib, temozolomide</b> combinations with radiation.
- <b>Inference clues (DIPG)</b>: If a DIPG patients record shows an
investigational drug given during the 6-week radiation (e.g., patient on
vorinostat during RT or receiving an EGFR inhibitor like erlotinib with RT),
that implies a clinical trial (since outside trials, radiation alone is typical).
Combination of <b>radiation + bevacizumab</b> is a strong sign of the St. Jude
DIPG-BATS trial arms</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=227%20CPT,radiation%20%2B%20bevacizumab%20%2B%20temozolomide"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[81]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=229%20DIPG,temozolomide%20233%20ETMR%20One"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>[82]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'><span lang=EN>,
whereas <b>radiation + panobinostat or pegapanimab (intratumoral)</b> would
indicate other PBTC/PNOC trials. For example, <b>panobinostat/panitumumab with
RT</b> would suggest PNOC007, and <b>paxalisib after RT</b> suggests a PBTC
study. Always look for mention of drug names not part of standard chemo  these
usually flag a specific trial.</span></span></span></span></span></p>

<span style='mso-bookmark:Xc9a637d338794c1a78ab22ec21473a54196862e'></span>

<h3><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><a
name=Xb7f0dec4df29c4fe663b97e692aeada3ebf5167><span lang=EN>Brain Tumor
Consortium and Institutional Trials</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'><span lang=EN>Aside
from COG and St. Jude, various consortium or single-institution protocols
exist: - <b>PBTC (Pediatric Brain Tumor Consortium)</b> trials often focus on
novel agents in refractory tumors. E.g., PBTC-026 (lenalidomide for DIPG),
PBTC-027 (cilengitide for DIPG), PBTC-045 (paxalisib for DIPG). These are
typically phase I/II with small numbers. - <b>Inference</b>: If a rare agent is
noted (e.g., <i>patient on lenalidomide during RT for brainstem glioma</i>),
checking PBTC protocols is warranted. The protocol number might even be
referenced in records if the patient was on trial. - <b>PNOC (Pacific
Neuro-Oncology Consortium)</b> trials similarly test targeted therapies. E.g.,
PNOC003 (Everolimus + Bevacizumab in recurrent DIPG)</span></span></span></span></span><a
href="https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/#:~:text=studies,with%20that%20of%20subjects"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'><span lang=EN>[44]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'><span lang=EN>,
PNOC013 (Nivolumab combos in DIPG). - <b>Inference</b>: Combination of multiple
targeted agents (like an immunotherapy drug nivolumab plus another inhibitor)
in a childs treatment points to a trial like PNOC013 rather than standard
care. - <b>Institutional protocols (e.g., St. Jude SJMB12, SJYC07)</b>: These
can be identified if one sees unique risk-group nomenclature or therapy
elements: - <b>St. Jude MB trials</b> stratify by molecular subgroup. If a
patients plan includes an extremely <b>reduced CSI dose (e.g., 18 Gy)</b> for
WNT-medulloblastoma, this was only done on trials like SJMB12</span></span></span></span></span><a
href="https://ascopubs.org/doi/full/10.1200/JCO.23.00008#:~:text=When%20Can%20We%20Retire%203%2C600,such%20that%20only%20the"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'><span lang=EN>[76]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'><span lang=EN>. -
Use of <b>smoothened inhibitors (vismodegib)</b> for SHH-medulloblastoma in a
child would also reflect a trial setting (SJMB12 Stratum S2). - <b>Multiple
risk strata with different therapies</b> mentioned in a summary (like Stratum
WNT vs SHH) indicate participation in a trial with molecular stratification
(SJMB12 or European PNET5).</span></span></span></span></span></p>

<span style='mso-bookmark:Xb7f0dec4df29c4fe663b97e692aeada3ebf5167'></span>

<h3><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><a
name=X73c5be34fa93f329c82f427e3e3061e20384c9f><span lang=EN>Neuroblastoma and
Other Solid Tumor Protocols</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>While
not strictly neuro-oncology, the list includes neuroblastoma (ANBL) and
others, which may appear if CNS metastatic or secondary CNS tumor involvement
is present:</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><b><span lang=EN>High-Risk
Neuroblastoma</span></b><span lang=EN>  e.g., <i>COG ANBL0532, ANBL1531</i>: -
<b>Hallmark regimen</b>: Induction chemo (56 cycles of multi-drug therapy
including cisplatin, etoposide, cyclophosphamide, doxorubicin)  surgery  <b>myeloablative
chemo with autologous stem cell transplant</b> (either single or tandem)</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[65]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN> 
radiation to primary site (21 Gy)  <b>anti-GD2 immunotherapy with isotretinoin</b>
(maintenance). - <b>Inference clues</b>: The presence of an <b>autologous stem
cell transplant</b> and subsequent <b>anti-GD2 immunotherapy (dinutuximab +
IL-2 + GM-CSF)</b> in a childs treatment plan is a giveaway of a COG high-risk
neuroblastoma protocol post-2010. Tandem transplants (two back-to-back
transplants) specifically indicate the randomization on ANBL0532 Arm B</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[65]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>
(or certain institutional approaches). If the chart notes tandem transplant,
that patient was on the experimental arm for high-risk NBL. Additionally,
isotretinoin given as six months of maintenance in a solid tumor context is
unique to neuroblastoma therapy</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[15]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><b><span lang=EN>Intermediate-Risk
Neuroblastoma</span></b><span lang=EN>  e.g., <i>COG ANBL0531</i>: - <b>Hallmark</b>:
Surgery and moderate chemotherapy (carboplatin, etoposide, cyclophosphamide,
doxorubicin) without transplant or immunotherapy</span></span></span></span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=154%20ANBL00B1%20155%20ANBL00P1%20156,chemotherapy%2C%20surgery"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[62]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>.
Number of cycles depends on clinical and biologic risk factors. - <b>Inference
clues</b>: If a neuroblastoma patients therapy stops after 48 chemo cycles
with no transplant or immunotherapy, and theyre labeled intermediate risk,
its likely ANBL0531 or similar. The specific drugs (no melphalan, no
immunotherapy) differentiate it from high-risk therapy.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><b><span lang=EN>Other
Solid Tumors</span></b><span lang=EN>: - <b>Wilms Tumor (Kidney)</b>: While not
neuro-onc, if seen, Wilms protocols (AREN series) are recognized by
vincristine/dactinomycin (2-drug) for low risk, adding doxorubicin for higher
stage, and whole abdominal or lung radiation if advanced. For example, a child
under 2 with stage I Wilms on only vincristine/dactinomycin for 18 weeks (no
radiation) was likely on AREN0532</span></span></span></span></span><a
href="https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/#:~:text=Study%20www,free%20and%20overall%20survival%20outcomes"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[83]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>. -
<b>Germ Cell Tumors (CNS)</b>: The ACNS1123/0232 trials for CNS germinoma used
carboplatin/etoposide chemo  reduced RT. Clue: 4 cycles of
carboplatin-etoposide then only 18 Gy whole-ventricular RT + boost  points to
ACNS0232</span></span></span></span></span><a
href="https://ascopubs.org/doi/10.1200/GO.22.00257#:~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>[84]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'><span lang=EN>. -
<b>Retinoblastoma</b> or other rare tumors might appear with unique therapy
(intra-arterial chemo, etc.), usually referenced by specific trial names in
notes (e.g., CHEERE trial).</span></span></span></span></span></p>

<span style='mso-bookmark:X73c5be34fa93f329c82f427e3e3061e20384c9f'></span>

<h3><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><a
name=X0cb37493f6c2928e774baa217c05624c95fed56><span lang=EN>Guidelines for
Inferring Protocol Enrollment</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>When
reviewing a pediatric oncology treatment summary, use these guidelines to match
it to a protocol:</span></span></span></span></span></p>

<ol style='margin-top:0in' start=1 type=1>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Identify the Diagnosis and Risk Level</span></b><span lang=EN>:
     Protocols are diagnosis-specific and often risk-adapted. Clues like
     average-risk medulloblastoma or high-risk ALL in the record will
     narrow down candidate trials (COG typically, by era).</span></span></span></span></span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Note Key Therapeutic Components</span></b><span lang=EN>:</span></span></span></span></span></li>
</ol>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l2 level1 lfo2'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>The <b>chemotherapy agents and
their combinations</b> can be signature identifiers. For instance:</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Nelarabine</span></b><span
lang=EN>  T-ALL trials (AALL0434)</span></span></span></span></span><a
href="https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric#:~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[3]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Carboplatin during radiation</span></b><span
lang=EN>  high-risk MB trials (ACNS0332)</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[11]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Isotretinoin</span></b><span
lang=EN> in a brain tumor context  ACNS0332 (medullo) or neuroblastoma
maintenance.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Anti-GD2 antibody</span></b><span
lang=EN>  neuroblastoma high-risk protocol (modern era).</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Thiotepa</span></b><span
lang=EN> and <b>autologous transplant</b> for a brain tumor under age 3  Head
Start or ACNS0334.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Temozolomide + Lomustine</span></b><span
lang=EN> for upfront glioma  ACNS0423</span></span></span></span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[36]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Bevacizumab + irinotecan +
temozolomide</span></b><span lang=EN> in recurrent MB  ACNS0821 TIB arm</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/33844469/#:~:text=NIH%20pubmed,The%20combination%20was%20relatively"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[48]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoNormal><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>**2024
NCCN Update:** Proton therapy is the preferred modality in many pediatric CNS
tumors due to reduced toxicity. Explicit mention of proton RT supports protocol
adherence.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l2 level1 lfo2'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Radiation fields and doses</span></b><span
lang=EN>:</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>CSI dose 23.4 vs 36 Gy
distinguishes standard vs high-risk medulloblastoma protocols</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[85]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>The use of CSI at all in a child
&lt;3 suggests recurrence or protocol deviation, since standard trials avoid it
(unless on a relapse trial or AT/RT at age ~2 where CSI might be considered
like ACNS0333 Arm II for &gt;12m old</span></span></span></span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=%283D,6%20weeks"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[26]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>).</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Whole ventricular irradiation of
18 Gy followed by boost implies a germinoma chemo/RT trial (ACNS0232)</span></span></span></span></span><a
href="https://ascopubs.org/doi/10.1200/GO.22.00257#:~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[84]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Proton vs photon mention: some
trials (PNOC or SJ) evaluate proton therapy differences (e.g., ACNS0831 had an
objective regarding proton vs photon outcomes</span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=therapy%20contributes%20to%20neurobehavioral%20morbidity,therapy%20followed%20by%20observation%20alone"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[86]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>).</span></span></span></span></span></p>

<ol style='margin-top:0in' start=5 type=1>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Surgical timing and additional procedures</span></b><span lang=EN>:</span></span></span></span></span></li>
</ol>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo5'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Second-look surgery after
initial chemo  common in protocols like ACNS0333 (AT/RT)</span></span></span></span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=After%20completion%20of%20induction%20therapy%2C,to%201%20of%202%20arm"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[87]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN> or
ACNS0334 (some patients had second resection after induction). If noted, it
shows the protocols strategy (improving resection after chemo).</span></span></span></span></span></p>

<ol style='margin-top:0in' start=6 type=1>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Compare Treatment Timing and Sequence</span></b><span lang=EN>:</span></span></span></span></span></li>
</ol>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l2 level1 lfo2'><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><![if !supportLists]><span
lang=EN style='mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin'><span
style='mso-list:Ignore'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Protocols have defined phase
timing. For example, ACNS0334 specifies <b>3 induction cycles, then within 6
weeks proceed to transplant</b></span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[74]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.
If you see long gaps or extra cycles, the patient may have gone off-protocol or
switched.</span></span></span></span></span></p>

<ol style='margin-top:0in' start=8 type=1>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span
     lang=EN>Maintenance therapy presence or absence is informative: Ependymoma
     standard has none, so if given, its a trial (ACNS0831). ALL always has
     maintenance (2+ years); if a leukemic patient doesnt, they were not on an
     established protocol (or data is incomplete).</span></span></span></span></span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Look for Explicit Mentions</span></b><span lang=EN>: Sometimes the
     protocol number or name is directly referenced in clinic notes or
     discharge summaries (e.g., treated per ACNS0331). The provided table and
     references can then be used to confirm details of that protocols regimen.</span></span></span></span></span></li>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2'><span style='mso-bookmark:
     Xf38c977c61f036247de3444d788f9a19e1e08b1'><span style='mso-bookmark:content'><span
     style='mso-bookmark:reference-guide-and-inference-guidelines'><span
     style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span
     lang=EN>Cross-Reference with Era</span></b><span lang=EN>: Trials
     open/close in specific years. If a therapy was given in, say, 2010 for
     average-risk medulloblastoma, ACNS0331 (opened ~20042012) is likely; by
     2018, ACNS0331 was closed and a successor (ACNS1422 or SJMB12 at St. Jude)
     might be in use. Use dates and the institution to infer if it was a COG
     protocol or an institutional one.</span></span></span></span></span></li>
</ol>

<p class=FirstParagraph><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>By
leveraging the above reference table and recognizing these patterns, an LLM or
clinician can infer with high confidence which protocol a patients treatment
followed. Always verify against the patients eligibility (age, risk) and any
mention of consent to a trial. The combination of <b>treatment components</b>, <b>structure</b>,
and <b>context</b> provides a fingerprint for each protocol. When uncertain,
one should consult protocol publications or clinical trial registries
(ClinicalTrials.gov, NCI PDQ) using key trial identifiers (which are provided
in the table where available, e.g., NCT numbers</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[6]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><a
href="https://ncicirb.org/node/2695#:~:text=Temozolomide%20with%20Irinotecan%20versus%20Temozolomide%3B,A%20Groupwide%20Phase%20II%20Study"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[43]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><b><span lang=EN>Sources:</span></b><span
lang=EN> The compiled data above is drawn from Childrens Oncology Group
clinical trial protocols and publications</span></span></span></span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=ABSTRACT%20Medulloblastoma%20is%20the%20most,randomly%20assigned%20to%20receive%20carboplatin"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[9]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[6]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>,
St. Jude trial reports</span></span></span></span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[85]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>,
and other authoritative sources including ClinicalTrials.gov and NCI summaries</span></span></span></span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=ARM%20I%3A%20Patients%20receive%20vincristine,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[27]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=I,VCEC"><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span></span></span></span></a><span
style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'><span
style='mso-bookmark:content'><span style='mso-bookmark:reference-guide-and-inference-guidelines'><span
style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'><span lang=EN>.
Specific citations are provided in the table for detailed verification of
dosing, sequence, and outcomes. These references include peer-reviewed articles
(e.g., JCO, Neuro-Oncology), which report the trials methods and results, as
well as protocol documents and summaries from clinical trial registries.</span></span></span></span></span></p>

<span style='mso-bookmark:X0cb37493f6c2928e774baa217c05624c95fed56'></span><span
style='mso-bookmark:reference-guide-and-inference-guidelines'></span><span
style='mso-bookmark:content'></span><span style='mso-bookmark:Xf38c977c61f036247de3444d788f9a19e1e08b1'></span>

<div class=MsoNormal align=center style='text-align:center'><span lang=EN
style='mso-no-proof:yes'>

<hr size=0 width="100%" align=center>

</span></div>

<p class=FirstParagraph><a name=citations></a><a
href="https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161#:~:text=,have%20other%20tests%20as%20needed"><span
style='mso-bookmark:citations'><span lang=EN>[1]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161#:~:text=Eligibility%3A"><span
style='mso-bookmark:citations'><span lang=EN>[2]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> NIH Clinical Center: Search the Studies</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161"><span
style='mso-bookmark:citations'><span lang=EN>https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric#:~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine"><span
style='mso-bookmark:citations'><span lang=EN>[3]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> T-cell acute lymphoblastic leukemia, pediatric | HemOnc.org</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric"><span
style='mso-bookmark:citations'><span lang=EN>https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/#:~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only"><span
style='mso-bookmark:citations'><span lang=EN>[4]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Table 8, Treatment Details in COG AALL0434 - Nelarabine (Atriance)</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/"><span
style='mso-bookmark:citations'><span lang=EN>https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance"><span
style='mso-bookmark:citations'><span lang=EN>[5]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=Age%20at%20enrollment%2C%20y%20Median,7"><span
style='mso-bookmark:citations'><span lang=EN>[10]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=Efficacy%20of%20Carboplatin%20and%20Isotretinoin,risk%20group%203%20medulloblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[13]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=Findings%C2%A0%20In%20this%20randomized%20clinical,risk%20group%203%20medulloblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[14]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033#:~:text=chemotherapy%20before%20radiotherapy%20as%20compared,279"><span
style='mso-bookmark:citations'><span lang=EN>[77]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Efficacy of Carboplatin and Isotretinoin in Children With High-risk
Medulloblastoma: A Randomized Clinical Trial From the Childrens Oncology Group
| Neuro-oncology | JAMA Oncology | JAMA Network</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033"><span
style='mso-bookmark:citations'><span lang=EN>https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:citations'><span lang=EN>[6]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=years,ototoxicity%20were%20monitored%20over%20time"><span
style='mso-bookmark:citations'><span lang=EN>[8]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/#:~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive"><span
style='mso-bookmark:citations'><span lang=EN>[85]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Children's Oncology Group Phase III Trial of Reduced-Dose and
Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk
Medulloblastoma - PubMed</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/34110925/"><span style='mso-bookmark:
citations'><span lang=EN>https://pubmed.ncbi.nlm.nih.gov/34110925/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=53%20%22ACNS0331%3A%20Arm%20V%20%288,years%20of%20age%2C%20SDCSI%2C%20PFRT"><span
style='mso-bookmark:citations'><span lang=EN>[7]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=154%20ANBL00B1%20155%20ANBL00P1%20156,chemotherapy%2C%20surgery"><span
style='mso-bookmark:citations'><span lang=EN>[62]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=match%20at%20L550%20157%20,enrolled%20on%20intermediate%20risk%20trial"><span
style='mso-bookmark:citations'><span lang=EN>[63]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation"><span
style='mso-bookmark:citations'><span lang=EN>[64]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation"><span
style='mso-bookmark:citations'><span lang=EN>[65]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=164%20,ANHL0131%3A%20Experimental%3A%20Consolidation%20with%20Vinblastine"><span
style='mso-bookmark:citations'><span lang=EN>[67]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=562%20Head%20Start%20II%3A%20induction,96%3A%20Stratum%20I%3A%20Option"><span
style='mso-bookmark:citations'><span lang=EN>[73]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=454%20SJMB03%20455%20SJMB03%3A%20Stratum,458%20SJMB12%3A%20Stratum%20N2%3A%20Intermediate"><span
style='mso-bookmark:citations'><span lang=EN>[75]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy"><span
style='mso-bookmark:citations'><span lang=EN>[79]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=227%20CPT,radiation%20%2B%20bevacizumab%20%2B%20temozolomide"><span
style='mso-bookmark:citations'><span lang=EN>[81]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c#:~:text=229%20DIPG,temozolomide%20233%20ETMR%20One"><span
style='mso-bookmark:citations'><span lang=EN>[82]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> CBTN _ REDCap_treatment.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_000000008ddc71f78c8e4acd437cfe6c"><span style='mso-bookmark:
citations'><span lang=EN>file://file_000000008ddc71f78c8e4acd437cfe6c</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=ABSTRACT%20Medulloblastoma%20is%20the%20most,randomly%20assigned%20to%20receive%20carboplatin"><span
style='mso-bookmark:citations'><span lang=EN>[9]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial"><span
style='mso-bookmark:citations'><span lang=EN>[11]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=this%20study%20is%20to%20determine,99701"><span
style='mso-bookmark:citations'><span lang=EN>[12]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective"><span
style='mso-bookmark:citations'><span lang=EN>[15]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=Note%3A%20Enrollment%20to%20Regimen%20C,The%20Study%20Committee"><span
style='mso-bookmark:citations'><span lang=EN>[17]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=C%20and%20D%29,risk"><span
style='mso-bookmark:citations'><span lang=EN>[18]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=receive%20carboplatin%20radiosensitization,Correlative%20biology"><span
style='mso-bookmark:citations'><span lang=EN>[70]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf#:~:text=demonstrated%20that%20it%20was%20feasible,ACNS0332%20previously%20included%20supratentorial"><span
style='mso-bookmark:citations'><span lang=EN>[72]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> cdn.clinicaltrials.gov</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf"><span
style='mso-bookmark:citations'><span lang=EN>https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/noa/article/7/1/vdaf054/8051863#:~:text=,risk%20medulloblastoma%20therapy.%20Isotretinoin"><span
style='mso-bookmark:citations'><span lang=EN>[16]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> A secondary analysis of the Children's Oncology Group ACNS0332 ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/noa/article/7/1/vdaf054/8051863"><span
style='mso-bookmark:citations'><span lang=EN>https://academic.oup.com/noa/article/7/1/vdaf054/8051863</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=INDUCTION%20THERAPY%20AND%20STEM%20CELL,4%20days"><span
style='mso-bookmark:citations'><span lang=EN>[19]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=hours%20after%20the%20start%20of,6%20CD34%2B%20cells%2Fkg%20have"><span
style='mso-bookmark:citations'><span lang=EN>[20]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=CONSOLIDATION%20THERAPY%20AND%20STEM%20CELL,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:citations'><span lang=EN>[21]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=dose%20carboplatin%20IV%20over%204,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:citations'><span lang=EN>[22]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=RADIATION%20THERAPY%3A%20Patients%20undergo%203,6%20weeks"><span
style='mso-bookmark:citations'><span lang=EN>[23]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=ARM%20I%20,any%20primary%20site%20or%20age"><span
style='mso-bookmark:citations'><span lang=EN>[24]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=ARM%20II%20,rescue%20as%20in%20Arm%20I"><span
style='mso-bookmark:citations'><span lang=EN>[25]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=%283D,6%20weeks"><span
style='mso-bookmark:citations'><span lang=EN>[26]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant#:~:text=After%20completion%20of%20induction%20therapy%2C,to%201%20of%202%20arm"><span
style='mso-bookmark:citations'><span lang=EN>[87]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Combination Chemotherapy, Radiation Therapy, and an Autologous
Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical
Teratoid/Rhabdoid Tumor of the Central Nervous System</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant"><span
style='mso-bookmark:citations'><span lang=EN>https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=ARM%20I%3A%20Patients%20receive%20vincristine,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:citations'><span lang=EN>[27]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=and%202%3B%20cisplatin%20IV%20over,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:citations'><span lang=EN>[28]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=OUTLINE%3A%20Patients%20are%20randomized%20to,1%20of%202%20treatment%20arms"><span
style='mso-bookmark:citations'><span lang=EN>[30]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=ARM%20II%3A%20Patients%20receive%20vincristine,for%203%20courses%20in%20the"><span
style='mso-bookmark:citations'><span lang=EN>[31]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024#:~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity"><span
style='mso-bookmark:citations'><span lang=EN>[74]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Combination Chemotherapy Followed By Peripheral Stem Cell Transplant
in Treating Young Patients With Newly Diagnosed Supratentorial Primitive
Neuroectodermal Tumors or High-Risk Medulloblastoma - NCI</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024"><span
style='mso-bookmark:citations'><span lang=EN>https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.sciencedirect.com/science/article/pii/S1878747923001307#:~:text=,with%20randomization%20of%20added"><span
style='mso-bookmark:citations'><span lang=EN>[29]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Medulloblastoma in the Modern Era: Review of Contemporary Trials ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.sciencedirect.com/science/article/pii/S1878747923001307"><span
style='mso-bookmark:citations'><span lang=EN>https://www.sciencedirect.com/science/article/pii/S1878747923001307</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409#:~:text=Phase%203%20randomized%20trial%20of,CCG9970316%20intensive%20chemotherapy%20backbone"><span
style='mso-bookmark:citations'><span lang=EN>[32]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409#:~:text=The%20primary%20objective%20of%20ACNS0334,CCG9970316%20intensive%20chemotherapy%20backbone"><span
style='mso-bookmark:citations'><span lang=EN>[33]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Phase 3 randomized trial of high-dose methotrexate for young ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409"><span
style='mso-bookmark:citations'><span lang=EN>https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=match%20at%20L447%20resection%20extent,Four%20weeks%20after"><span
style='mso-bookmark:citations'><span lang=EN>[34]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=resection%20extent,Four%20weeks%20after"><span
style='mso-bookmark:citations'><span lang=EN>[35]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks"><span
style='mso-bookmark:citations'><span lang=EN>[36]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=designed%20to%20determine%20whether%20lomustine,DNA"><span
style='mso-bookmark:citations'><span lang=EN>[37]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=participants%20treated%20with%20adjuvant%20temozolomide,comparison%20by%20resection%20extent%2C%20the"><span
style='mso-bookmark:citations'><span lang=EN>[38]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=radiation%20with%20adjuvant%20and%20concurrent,based%20therapies.1"><span
style='mso-bookmark:citations'><span lang=EN>[39]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/#:~:text=temozolomide%20to%20radiotherapy%20significantly%20increased,The%20study%20found"><span
style='mso-bookmark:citations'><span lang=EN>[52]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN><span style='mso-spacerun:yes'> </span>Phase 2 study of concurrent
radiotherapy and temozolomide followed by temozolomide and lomustine in the
treatment of children with high-grade glioma: a report of the Children's
Oncology Group ACNS0423 study - PMC </span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/"><span
style='mso-bookmark:citations'><span lang=EN>https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/#:~:text=ACNS0822%20was%20a%20feasibility%20and,received%20vorinostat%20230%20mg%2Fm2%2Fdose"><span
style='mso-bookmark:citations'><span lang=EN>[40]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> TR-14: A FEASIBILITY AND RANDOMIZED PHASE II STUDY ... - NIH</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/"><span
style='mso-bookmark:citations'><span lang=EN>https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/40487589/#:~:text=,TIB%20cycle%20includes%20oral"><span
style='mso-bookmark:citations'><span lang=EN>[41]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/40487589/#:~:text=Children%20with%20medulloblastoma%20treated%20with,TIB%20cycle%20includes%20oral"><span
style='mso-bookmark:citations'><span lang=EN>[46]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Children with medulloblastoma treated with modified ACNS0821 ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/40487589/"><span style='mso-bookmark:
citations'><span lang=EN>https://pubmed.ncbi.nlm.nih.gov/40487589/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://link.springer.com/article/10.1007/s40278-025-88222-5#:~:text=Case%201%3A%20A%20child%20with,mg%2Fm2per%20day%20for%20the"><span
style='mso-bookmark:citations'><span lang=EN>[42]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Bevacizumab/Irinotecan/Temozolomide | Reactions Weekly</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://link.springer.com/article/10.1007/s40278-025-88222-5"><span
style='mso-bookmark:citations'><span lang=EN>https://link.springer.com/article/10.1007/s40278-025-88222-5</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ncicirb.org/node/2695#:~:text=Temozolomide%20with%20Irinotecan%20versus%20Temozolomide%3B,A%20Groupwide%20Phase%20II%20Study"><span
style='mso-bookmark:citations'><span lang=EN>[43]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://ncicirb.org/node/2695#:~:text=ACNS0821,IND%23%207921%29%20for%20Recurrent%2FRefractory"><span
style='mso-bookmark:citations'><span lang=EN>[45]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> ACNS0821 | NCICIRB</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ncicirb.org/node/2695"><span style='mso-bookmark:citations'><span
lang=EN>https://ncicirb.org/node/2695</span></span><span style='mso-bookmark:
citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/#:~:text=studies,with%20that%20of%20subjects"><span
style='mso-bookmark:citations'><span lang=EN>[44]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> ACNS0821 - Clinical Research Studies - All IN for Health</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/"><span
style='mso-bookmark:citations'><span lang=EN>https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/33844469/#:~:text=NIH%20pubmed,The%20combination%20was%20relatively"><span
style='mso-bookmark:citations'><span lang=EN>[47]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/33844469/#:~:text=NIH%20pubmed,The%20combination%20was%20relatively"><span
style='mso-bookmark:citations'><span lang=EN>[48]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Report of a COG randomized Phase II screening trial - PubMed - NIH</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/33844469/"><span style='mso-bookmark:
citations'><span lang=EN>https://pubmed.ncbi.nlm.nih.gov/33844469/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ncicirb.org/node/2696#:~:text=A%20Randomized%20Phase%20II%2FIII%20Study,7921%29%20and%20Local"><span
style='mso-bookmark:citations'><span lang=EN>[49]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> ACNS0822 | NCICIRB</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ncicirb.org/node/2696"><span style='mso-bookmark:citations'><span
lang=EN>https://ncicirb.org/node/2696</span></span><span style='mso-bookmark:
citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_CHILDRE#:~:text=The%20COG%20ACNS0822%20trial%20compared,conventional%20RT%20followed%20by"><span
style='mso-bookmark:citations'><span lang=EN>[50]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> tr-14 * a feasibility and randomized phase ii study of vorinostat ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_CHILDRE"><span
style='mso-bookmark:citations'><span lang=EN>https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_CHILDRE</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/38596718/#:~:text=Vorinostat%2C%20temozolomide%20or%20bevacizumab%20with,children%20with%20newly%20diagnosed%20HGG"><span
style='mso-bookmark:citations'><span lang=EN>[51]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://pubmed.ncbi.nlm.nih.gov/38596718/#:~:text=Vorinostat%2C%20temozolomide%20or%20bevacizumab%20with,children%20with%20newly%20diagnosed%20HGG"><span
style='mso-bookmark:citations'><span lang=EN>[54]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Vorinostat, temozolomide or bevacizumab with irradiation and ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/38596718/"><span style='mso-bookmark:
citations'><span lang=EN>https://pubmed.ncbi.nlm.nih.gov/38596718/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.qarc.org/COG/HighGradeGliomas_.pdf#:~:text=,%E2%80%93"><span
style='mso-bookmark:citations'><span lang=EN>[53]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> [PDF] Pediatric High Grade Glioma</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.qarc.org/COG/HighGradeGliomas_.pdf"><span style='mso-bookmark:
citations'><span lang=EN>https://www.qarc.org/COG/HighGradeGliomas_.pdf</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html#:~:text=,radiation%20therapy%20in%20treating%20glioma"><span
style='mso-bookmark:citations'><span lang=EN>[55]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Vorinostat, Temozolomide, or Bevacizumab in Combination With ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html"><span
style='mso-bookmark:citations'><span lang=EN>https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.sciencedirect.com/science/article/pii/S245210942100049X#:~:text=Effect%20of%20Postoperative%20Radiation%20Therapy,The%20purpose%20of%20this"><span
style='mso-bookmark:citations'><span lang=EN>[56]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Effect of Postoperative Radiation Therapy Timing on Survival in ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.sciencedirect.com/science/article/pii/S245210942100049X"><span
style='mso-bookmark:citations'><span lang=EN>https://www.sciencedirect.com/science/article/pii/S245210942100049X</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=I,VCEC"><span
style='mso-bookmark:citations'><span lang=EN>[57]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=children%20with%20completely%20resected%20ependymoma,VCEC"><span
style='mso-bookmark:citations'><span lang=EN>[58]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=The%20primary%20aim%20of%20this,One%20arm%20studied"><span
style='mso-bookmark:citations'><span lang=EN>[59]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=The%20primary%20aim%20of%20this,One%20arm%20studied"><span
style='mso-bookmark:citations'><span lang=EN>[60]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368#:~:text=therapy%20contributes%20to%20neurobehavioral%20morbidity,therapy%20followed%20by%20observation%20alone"><span
style='mso-bookmark:citations'><span lang=EN>[86]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Maintenance Chemotherapy or Observation Following Induction
Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed
Ependymoma - NCI</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368"><span
style='mso-bookmark:citations'><span lang=EN>https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy#:~:text=Should%20adjuvant%20maintenance%20chemotherapy%20be,SIOP%20Ependymoma%20trial%20in%20Europe"><span
style='mso-bookmark:citations'><span lang=EN>[61]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Should adjuvant maintenance chemotherapy be provided to</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy"><span
style='mso-bookmark:citations'><span lang=EN>https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/#:~:text=,risk%20Group%203%20medulloblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[66]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> The Largest High-Risk Medulloblastoma Trial Makes Monumental ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/"><span
style='mso-bookmark:citations'><span lang=EN>https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/#:~:text=Study%20www,free%20and%20overall%20survival%20outcomes"><span
style='mso-bookmark:citations'><span lang=EN>[68]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/#:~:text=Study%20www,free%20and%20overall%20survival%20outcomes"><span
style='mso-bookmark:citations'><span lang=EN>[83]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Promising Results From Children's Oncology Group AALL0434 Study</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/"><span
style='mso-bookmark:citations'><span lang=EN>https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/32552472/#:~:text=Results%20From%20Children%27s%20Oncology%20Group,LL"><span
style='mso-bookmark:citations'><span lang=EN>[69]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Results From Children's Oncology Group AALL0434 - PubMed - NIH</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://pubmed.ncbi.nlm.nih.gov/32552472/"><span style='mso-bookmark:
citations'><span lang=EN>https://pubmed.ncbi.nlm.nih.gov/32552472/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/#:~:text=High,1185.%20doi%3A%2010.1200%2FJCO"><span
style='mso-bookmark:citations'><span lang=EN>[71]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> High-dose chemotherapy with autologous hematopoietic stem cell ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/"><span
style='mso-bookmark:citations'><span lang=EN>https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ascopubs.org/doi/full/10.1200/JCO.23.00008#:~:text=When%20Can%20We%20Retire%203%2C600,such%20that%20only%20the"><span
style='mso-bookmark:citations'><span lang=EN>[76]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> When Can We Retire 3,600 cGy Craniospinal Irradiation in ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ascopubs.org/doi/full/10.1200/JCO.23.00008"><span
style='mso-bookmark:citations'><span lang=EN>https://ascopubs.org/doi/full/10.1200/JCO.23.00008</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf#:~:text=,volume%20in%20the%20ongoing"><span
style='mso-bookmark:citations'><span lang=EN>[78]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> [PDF] Pediatric Radiation Oncology</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf"><span
style='mso-bookmark:citations'><span lang=EN>http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264#:~:text=TEMOZOLOMIDE%20,GROUP%20STUDY%20ACNS0822"><span
style='mso-bookmark:citations'><span lang=EN>[80]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> tr-14 a feasibility and randomized phase ii study of vorinostat ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264"><span
style='mso-bookmark:citations'><span lang=EN>https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ascopubs.org/doi/10.1200/GO.22.00257#:~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and"><span
style='mso-bookmark:citations'><span lang=EN>[84]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> Outcome of Children and Adolescents With Primary Intracranial ...</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="https://ascopubs.org/doi/10.1200/GO.22.00257"><span style='mso-bookmark:
citations'><span lang=EN>https://ascopubs.org/doi/10.1200/GO.22.00257</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

</div>

</body>

</html>
